WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Debra G. Silberg, MD, PhD, vice president of clinical development at Shire, discusses the company’s current pipeline for gastrointestinal therapies.
“Shire has had an increasing commitment to the study of GI diseases and, currently, we have two programs that are marketed: one is short bowel syndrome and the other in ulcerative colitis for mild to moderate therapies,” Silberg told Healio Gastroenterology and Liver Disease. “This commitment has increased, though, over the years, and we now have programs in our pipeline for eosinophilic esophagitis, moderate to severe ulcerative colitis and Crohn’s disease, and chronic idiopathic constipation, to name a few.”
Among the topics Silberg discussed was the new drug application Shire recently submitted for prucalopride. Prucalopride is a selective 5-HT4 agonist designed to induce intestinal peristalsis for increased gut motility in patients with chronic idiopathic constipation. Shire expects an FDA response by December 2018.
“This heritage we have in GI from Shire is continuing to grow and I’m very excited about the future prospects for Shire in this space,” Silberg said.
Disclosure: Silberg is an employee of Shire.